Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.

Lee YY, Kim HP, Kang MJ, Cho BK, Han SW, Kim TY, Yi EC.

Exp Mol Med. 2013 Nov 22;45:e64. doi: 10.1038/emm.2013.115.

2.

MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.

Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR.

Mol Cancer Ther. 2012 Mar;11(3):660-9. doi: 10.1158/1535-7163.MCT-11-0754. Epub 2012 Jan 11.

3.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

4.

Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.

Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, Im SA, Bang YJ, Kim TY.

Oncogene. 2014 Jun 19;33(25):3334-41. doi: 10.1038/onc.2013.285. Epub 2013 Jul 22.

PMID:
23873022
5.

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.

Mol Cancer Ther. 2010 Jun;9(6):1489-502. doi: 10.1158/1535-7163.MCT-09-1171. Epub 2010 May 25. Erratum in: Mol Cancer Ther. 2011 Nov;10(11):2211.

6.

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M.

Clin Cancer Res. 2012 May 1;18(9):2603-12. doi: 10.1158/1078-0432.CCR-11-2750. Epub 2012 Mar 8.

7.

Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.

Vazquez-Martin A, Oliveras-Ferraros C, Colomer R, Brunet J, Menendez JA.

Ann Oncol. 2008 Jun;19(6):1097-109. doi: 10.1093/annonc/mdm589. Epub 2008 Feb 17.

8.

Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.

Sato Y, Yashiro M, Takakura N.

Cancer Sci. 2013 Dec;104(12):1618-25. doi: 10.1111/cas.12290. Epub 2013 Oct 28.

9.

Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.

Li B, Chang CM, Yuan M, McKenna WG, Shu HK.

Cancer Res. 2003 Nov 1;63(21):7443-50.

10.

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.

Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR.

Mol Cancer Ther. 2008 Nov;7(11):3499-508. doi: 10.1158/1535-7163.MCT-08-0374. Epub 2008 Oct 30.

11.

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.

Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K.

Oncogene. 2011 Sep 29;30(39):4097-106. doi: 10.1038/onc.2011.111. Epub 2011 Apr 18.

PMID:
21499301
12.

PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.

Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A.

Cell Signal. 2010 Sep;22(9):1369-78. doi: 10.1016/j.cellsig.2010.05.006. Epub 2010 May 12.

13.

Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.

Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.

Endocr Relat Cancer. 2005 Dec;12(4):983-98.

14.

Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.

Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L.

Cancer Res. 2005 Nov 15;65(22):10524-35.

15.

Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.

Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H.

J Hematol Oncol. 2012 Jul 11;5:16. doi: 10.1186/1756-8722-5-16.

16.

[Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].

Zhang XJ, Zhang L, Liu YP, Xu HM, Sun P, Song JG, Luo YH.

Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):181-6. doi: 10.3760/cma.j.issn.0253-3766.2013.03.005. Chinese.

PMID:
23879997
17.

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.

J Cell Physiol. 2006 May;207(2):420-7.

PMID:
16419029
18.

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.

Yuen HF, Abramczyk O, Montgomery G, Chan KK, Huang YH, Sasazuki T, Shirasawa S, Gopesh S, Chan KW, Fennell D, Janne P, El-Tanani M, Murray JT.

Biosci Rep. 2012 Aug;32(4):413-22. doi: 10.1042/BSR20120050.

20.

RON confers lapatinib resistance in HER2-positive breast cancer cells.

Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L.

Cancer Lett. 2013 Oct 28;340(1):43-50. doi: 10.1016/j.canlet.2013.06.022. Epub 2013 Jun 27.

PMID:
23811285
Items per page

Supplemental Content

Write to the Help Desk